Brief: UCB Introduces New 4-Year Data For Bimzelx
Sept 25 (Reuters) - Ucb SA UCB.BR :
* PRESENTS NEW 4-YEAR DATA FOR BIMZELX ® ▼(BIMEKIZUMAB) IN
MODERATE TO SEVERE PLAQUE PSORIASIS AT EADV 2024
Source text: https://shorturl.at/JSaWC
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside